Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

John Jones, MD, Charlotte Pawlyn, MBBChir, Annamaria Brioli, David A Cairns, PhD, Ana Quartillo, Rachel Sigsworth, Helen Howard, PhD, Corinne Collett, Jacqueline Ouzman, PhD, Walter Gregory, PhD, Nigel Russell, Graham H Jackson, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 4744.

https://doi.org/10.1182/blood.V124.21.4744.4744

Published: 2014

Journal Articles

Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA

Martin F Kaiser, MD, Paula Proszek, MSc, Dil Begum, BSc, Nasrin Dahir, BSc, Brian A Walker, PhD, Suvi Savola, PhD, Eileen M Boyle, MD, David C Johnson, PhD, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2014) 124 (21): 5168.

https://doi.org/10.1182/blood.V124.21.5168.5168

Published: 2014

Journal Articles

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Blood (2014) 124 (21): 723.

https://doi.org/10.1182/blood.V124.21.723.723

Published: 2014

Journal Articles

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Blood (2014) 124 (21): 637.

https://doi.org/10.1182/blood.V124.21.637.637

Published: 2014

Journal Articles

High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation

Martin F Kaiser, MD, Alexander Murison, PhD, Charlotte Pawlyn, MBBChir, Eileen M Boyle, MD, David C Johnson, PhD, Brian A Walker, PhD, Ping Wu, MBBS, MSc, Dil Begum, BSc, Nasrin Dahir, BSc, Christopher P Wardell, PhD, Paula Proszek, MSc, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 2189.

https://doi.org/10.1182/blood.V124.21.2189.2189

Published: 2014

Journal Articles

The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact

Blood (2014) 124 (21): 2194.

https://doi.org/10.1182/blood.V124.21.2194.2194

Published: 2014

Journal Articles

High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients

Martin F Kaiser, MD, Eileen M Boyle, MD, Brian A Walker, PhD, Charlotte Pawlyn, MBBChir, Dil Begum, BSc, Paula Proszek, MSc, Nasrin Dahir, BSc, David C Johnson, PhD, Suvi Savola, PhD, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 172.

https://doi.org/10.1182/blood.V124.21.172.172

Published: 2014

Journal Articles

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

Blood (2014) 124 (21): 640.

https://doi.org/10.1182/blood.V124.21.640.640

Published: 2014

Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 3378.

https://doi.org/10.1182/blood.V122.21.3378.3378

Published: 2013

Journal Articles

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, Christopher Parrish, MD, James D. Cavenagh, MD, John A Snowden, MD, FRCP, FRCPath, Sheila J O'Connor, Roger G Owen, MD, Julia Brown, MB, Treen Morris

Blood (2013) 122 (21): 1884.

https://doi.org/10.1182/blood.V122.21.1884.1884

Published: 2013

Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris

Blood (2013) 122 (21): 765.

https://doi.org/10.1182/blood.V122.21.765.765

Published: 2013

NARROW

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation

The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact

High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only